Can we predict myeloma before it starts? new study aims to find out
NCT ID NCT03689595
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
The PROMISE study is enrolling 30,000 people at high risk for multiple myeloma, including African Americans and those with a family history of blood cancers. Participants provide blood samples so researchers can track changes over time and identify who progresses to myeloma. The goal is to better understand risk factors and potentially catch the disease earlier.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help identify who is most likely to develop multiple myeloma, enabling earlier monitoring or intervention.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may take years to emerge.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact